| [1] |
WANG Zhi, ZHOU Xin, HE Xueru, FU Yuhao, XUN Xuejiao, LI Ying, DONG Zhanjun.
Clinical research progress of palbociclib in treatment of breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 205-213.
|
| [2] |
DAI Jiahui, SUN Sijia, XIE Xuefeng.
Quality management and indicator system for clinical trials of medical devices
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 51-58.
|
| [3] |
CHEN Jianfang, LOU Donghua.
Design of case report form for oncology clinical trials based on CDASH
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 762-767.
|
| [4] |
LIU Xing, LU Xiaoran, WU Ying, YU Haitao, WANG Xiaomin.
Ethical analysis and countermeasures of artificial intelligence application in clinical trials
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 322-327.
|
| [5] |
ZHU Lili, ZHU Xiuxiu, WANG Wenjun, ZHANG Hailin, LIN Li.
Clinical trials of inhalation in pediatric population in China
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 178-183.
|
| [6] |
ZHENG Ying, ZHANG Ling, YAO Li, WANG Qianhe, ZHU Kexiang.
Research progress of PARP inhibitors in pancreatic cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 108-115.
|
| [7] |
SHE Zhihua, CHEN Zhou, LIANG Songyue.
Construction of informatization system of drug clinical trials ethical review based on cloud architecture
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1023-1030.
|
| [8] |
OUYANG Chenxi, HUANG Jie, XIANG Yuxia, WANG Xiaomin.
Ethical issues and countermeasures of early phase trials
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 802-807.
|
| [9] |
Pazilaiti YASEN, YUAN Hao, LU Hong, ZHENG Ya, WANG Yuping, ZHOU Yongning.
Research progress in clinical trials of targeted drugs for gastric cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 454-461.
|
| [10] |
ZHANG Qian, HU Wei, YU Bin, QIN Huiling, CHEN Mingzhuang, LU Chao.
Information construction of drug clinical trials based on literature analysis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 182-189.
|
| [11] |
YU Zhaolei, BAI Jianling, YU Hao, ZHAO Yang.
Development of tools for clinical trial information retrieval and Meta-analysis based on R-Shiny: Taking non-small cell lung cancer as an example
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 984-991.
|
| [12] |
JIANG Haihong, LI Xiao, LIU Yang.
Four dimensions of receiving overseas clinical trial data about drug and medical devices
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 835-840.
|
| [13] |
ZHONG Zihang, CHEN Feng, YUAN Ying, CHENG Jiancheng, YU Xuanxuan, YANG Min, TAN Mingmin, ZHAO Yang, BAI Jianling, YU Hao.
A novel model-assisted design in phase I clinical trials: Bayesian optimal interval design
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 640-648.
|
| [14] |
HAO Yuqi, XIAO Yao, WANG Qian, JIANG Xingxu.
Therapeutic drugs and treatment of SARS-CoV-2
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 716-720.
|
| [15] |
ZHANG Zhengfu, LI Meng, WANG Jianan.
Protection of subjects' legal rights, welfare and safety in clinical trials of COVID-19
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 421-425.
|
